News - Starpharma

Latest News

US patent granted for DEP Bcl2/xL inhibitor conjugates

Jun 12th, 2019

Starpharma announced the first patent for DEP^® Bcl2/xL inhibitor conjugates, developed in collaboration with AstraZeneca, has been granted by the US Patent and Trademark Office. These patented DEP^® Bcl2/xL inhibitor conjugates combine Starpharma’s innovative DEP^® delivery technology with AstraZeneca’s novel Bcl2/xL inhibitors, which are being investigated for treating various cancers, including leukemias.

Okamoto launches VivaGel® condom in Japan

Jun 4th, 2019

Starpharma today announced that the VivaGel^® condom has been launched in Japan under Okamoto’s leading and highly successful Zero Zero Three (003) brand. This is the first condom with antiviral coating in Japan and will also carry Starpharma’s VivaGel^® brand.

Starpharma signs second oncology agreement with AstraZeneca

Jun 3rd, 2019

Starpharma today announced a Development and Option Agreement with AstraZeneca (LON: AZN) to progress the development of a Dendrimer Enhanced Product (DEP^®) version of an undisclosed AstraZeneca major marketed oncology medicine. This is the second DEP^® commercial agreement Starpharma has signed with AstraZeneca, the first agreement being a multiproduct licence which covers novel oncology drug candidates such as AZD0466 (a Bcl2/xL inhibitor).

Starpharma presents at UBS Healthcare Conference

May 29th, 2019

Starpharma has been invited to present today at the UBS Australian Emerging Companies Conference - Healthcare and Biotech – in Sydney. The UBS Healthcare Conference provides Starpharma with an opportunity to present to approximately 100 institutional investors.

In the media

Markets Live: Starpharma shares rise 13 per cent following Australian launch of VivaGel BV

Apr 16th, 2019

The Australian Financial Review reported Starpharma’s share price rose 13 per cent following the company’s announcement that VivaGel® BV was launched nationwide in Australia. The article noted this was the first of many launches for the breakthrough BV product.

Read the full coverage here (paywall)

Starpharma’s US license for VivaGel® BV covered by Biotech Dispatch

Dec 20th, 2018

Biotech Dispatch featured the news that Starpharma had signed a sales and marketing license agreement for VivaGel® BV for the US market with ITF Pharma. The piece highlighted that upon launch, VivalGel® BV will be ITF Pharma’s top priority women’s health product.

To read the article, click here.

Starpharma’s $142M+ US license deal for VivaGel® BV featured in Proactive Investors

Dec 20th, 2018

Online investor portal Proactive Investors highlighted Starpharma’s VivaGel® BV US license deal with ITF Pharma, worth $142 million plus escalating double digit royalties. The piece noted ITF Pharma’s strong pedigree in women’s health and their high-calibre team.

To read the article, click here.

Small Caps publication covers DEP® irinotecan candidate’s positive performance in pancreatic cancer model

Sep 5th, 2018

Small Caps, a specialist investment publication, covered the positive news that Starpharma’s DEP® irinotecan showed complete tumour regression and 100% survival in a human pancreatic cancer model.

Read the full article here.